These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1561158)

  • 21. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study.
    Blacher J; Evans A; Arveiler D; Amouyel P; Ferrières J; Bingham A; Yarnell J; Haas B; Montaye M; Ruidavets JB; Ducimetière P;
    J Hum Hypertens; 2010 Jan; 24(1):19-26. PubMed ID: 19474798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological management of dyslipidemia in high and very high cardiovascular risk patients.
    Pascual Fuster V
    Rev Esp Sanid Penit; 2016 Dec; 18(3):95-108. PubMed ID: 27831597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on statins and other lipid-lowering drugs.
    Miller CA
    Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910
    [No Abstract]   [Full Text] [Related]  

  • 24. Severely frail elderly patients do not need lipid-lowering drugs.
    Mallery LH; Moorhouse P; McLean Veysey P; Allen M; Fleming I
    Cleve Clin J Med; 2017 Feb; 84(2):131-142. PubMed ID: 28198686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dyslipidemias and the primary prevention of cardiovascular disease: analysis of the FAMUS primary care register.
    Xhignesse M; Laplante P; Niyonsenga T; Courteau J; Grant AM
    Can J Cardiol; 2000 Jul; 16(7):879-85. PubMed ID: 10934306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guest Editors Henry Pownall and Antonio Gotto Offer Insight and Expertise on the topic of Lipids and Cardiovascular Disease.
    Methodist Debakey Cardiovasc J; 2019; 15(1):4. PubMed ID: 31049142
    [No Abstract]   [Full Text] [Related]  

  • 27. Reducing drug usage and adverse effects. Part III: Cardiovascular disease and hyperlipidemia.
    Baron M
    Health Care Food Nutr Focus; 2005 Jun; 22(6):7-11. PubMed ID: 15923907
    [No Abstract]   [Full Text] [Related]  

  • 28. Hyperlipidemia, Disease Associations, and Top 10 Potential Drug Targets: A Network View.
    Rai S; Bhatnagar S
    OMICS; 2016 Mar; 20(3):152-68. PubMed ID: 26983022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical recommendations for the management of hyperlipidemia.
    Fischer S; Schatz U; Julius U
    Atheroscler Suppl; 2015 May; 18():194-8. PubMed ID: 25936326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.
    Gomaraschi M; Adorni MP; Banach M; Bernini F; Franceschini G; Calabresi L
    Handb Exp Pharmacol; 2015; 224():593-615. PubMed ID: 25523003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Update of lipid lowering therapy].
    Riesen WF; Mordasini RC
    Praxis (Bern 1994); 2008 Nov; 97(22):1179-84. PubMed ID: 18979436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperlipidemia after cardiac transplantation: be aware and possibly wary of drug therapy for lowering of serum lipids.
    Butman SM
    Am Heart J; 1991 May; 121(5):1585-90. PubMed ID: 2018001
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals.
    Micallef MA; Garg ML
    Atherosclerosis; 2009 Jun; 204(2):476-82. PubMed ID: 18977480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperlipidaemia and cardiovascular disease.
    Blum C
    Curr Opin Lipidol; 1996 Apr; 7(2):U57-64. PubMed ID: 8743909
    [No Abstract]   [Full Text] [Related]  

  • 36. [Time for more active lipid-lowering treatment of patients with diabetes. Negative effect of hyperlipidemia on beta-cells is a neglected field].
    Sjöholm A
    Lakartidningen; 1998 Dec; 95(50):5750-2. PubMed ID: 9889494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Other antihyperuricemic agents].
    Ogino K; Igawa O; Hisatome I
    Nihon Rinsho; 2008 Apr; 66(4):754-7. PubMed ID: 18409527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

  • 39. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration.
    Ulbricht C; Basch E; Szapary P; Hammerness P; Axentsev S; Boon H; Kroll D; Garraway L; Vora M; Woods J;
    Complement Ther Med; 2005 Dec; 13(4):279-90. PubMed ID: 16338199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice.
    Lindgren P; Borgström F; Stålhammar J; Alemao E; Yin DD; Jönsson L
    Eur J Cardiovasc Prev Rehabil; 2005 Dec; 12(6):530-4. PubMed ID: 16319541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.